Mark Foley, Revance CEO (Revance via Vimeo)
August 12, 2024 11:35 AM EDT
Deals

Re­vance to be ac­quired for $900M+ as Botox trade se­crets law­suit con­tin­ues

Max Gelman

Senior Editor

Re­vance Ther­a­peu­tics, the mak­er of Botox com­peti­tor Daxxi­fy, will be ac­quired for more than $900 mil­lion.

Crown Lab­o­ra­to­ries will buy out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Ex­clu­sive: A male con­tra­cep­tive may pre­vent 99% of preg­nan­cies. Now it’s up to a small biotech to fin­ish test­ing it

Roche's dual GLP-1/GIP re­sults show promis­ing weight loss, but al­so high rates of vom­it­ing

House pass­es Biose­cure Act, send­ing Chi­nese biotech ban to Sen­ate

Ex­clu­sive: Bain scoops up $3B for fourth life sci­ences fund af­ter hand­ful of M&A deals

Roivant un­veils its next deal, hop­ing for TL1A-sized po­ten­tial from a shelved Bay­er lung dis­ease ther­a­py

Io­n­is’ $500M of­fer­ing; Terns aims to raise $125M 

A service from the Financial Times